(Q42653303)

English

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease

scientific article

Statements

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease (English)

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit